Lack of paradoxical bronchoconstriction after administration of tiotropium via Respimat® Soft Mist™ Inhaler in COPD by Hodder, Rick et al.
© 2011 Hodder et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
International Journal of COPD 2011:6 245–251
International Journal of COPD Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
245
OrIgInAL reseArCH
open access to scientific and medical research
Open Access Full Text Article
DOI: 10.2147/COPD.S16094
Lack of paradoxical bronchoconstriction after 
administration of tiotropium via respimat®  
soft Mist™ Inhaler in COPD
rick Hodder1
Demetri Pavia2
Angela Lee2
eric Bateman3
1Divisions of Pulmonary and Critical 
Care, University of Ottawa, Ottawa, 
On, Canada; 2Boehringer Ingelheim 
Limited, Bracknell, england, UK; 
3Division of Pulmonology, Department 
of Medicine, University of Cape Town, 
Cape Town, south Africa
Correspondence: rick Hodder 
Divisions of Pulmonary and  
Critical Care, The Ottawa  
Hospital, 1053 Carling Avenue,  
Ottawa, Ontario, Canada 
Tel +1 613 761 4130 
Fax +1 613 761 4152 
email rhodder@toh.on.ca.
Abstract: Bronchoconstriction has been reported in asthma and chronic obstructive 
  pulmonary disease (COPD) patients after administration of some aqueous inhalation   solutions. 
We   investigated the incidence of this event during long-term clinical trials of tiotropium d  elivered 
via Respimat® Soft Mist™ Inhaler (SMI). We retrospectively analyzed pooled data from 
two identical Phase III clinical trials, in which 1990 patients with COPD received 48 weeks’ 
treatment with once-daily tiotropium (5 or 10 µg) or placebo inhaled via Respimat® SMI. We 
recorded the incidence of bronchospasm and of a range of respiratory events that could suggest 
bronchoconstriction during the first 30 minutes after inhalation of study treatment on each of the 
eight test days. No patients reported bronchospasm. Six patients (0.3%) reported a combination 
of at least two events suggestive of bronchoconstriction, and 21 (1.1%) reported either rescue 
medication use or a respiratory adverse event. Asymptomatic falls in forced expiratory volume 
in one second (FEV1) of $15% were recorded on all test days, with no change in incidence over 
time, and affected 8.2% of those in the tiotropium groups and 14.5% of those on placebo. In 
COPD patients receiving long-term treatment with tiotropium 5 or 10 µg via Respimat® SMI, 
no bronchospasm was recorded, and the number of events possibly indicative of paradoxical 
bronchoconstriction was very low.
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Introduction
Aqueous aerosol delivery via nebulizers has been an important element in the t  reatment 
and prophylaxis of many obstructive lung diseases, particularly in emergency settings. 
More recently, the development of smaller portable inhaler devices that deliver small 
doses of aqueous aerosols has expanded the therapeutic options available for the 
everyday treatment of chronic obstructive pulmonary disease (COPD) and asthma. 
One such device is Respimat® Soft Mist™ Inhaler (SMI), a novel multidose metered-
dose inhaler that uses mechanical energy instead of fluorocarbon propellants to deliver 
a fine and slow-moving aerosol spray.1,2 The device allows inhaled drug to be more 
efficiently delivered to the lungs than the pressurized metered-dose inhaler (pMDI),3 
which enables a lower nominal dose of bronchodilator to be delivered.4,5 Currently, 
two bronchodilators are approved for marketing in the Respimat® SMI formulation, 
the long-acting anticholinergic tiotropium (Spiriva®) and a combination of ipratropium 
and fenoterol (Berodual®).
The purpose of the present analysis was to investigate whether inhalation of 
tiotropium aqueous solution via Respimat® SMI is associated with administration-
related bronchoconstriction in patients with COPD. This phenomenon has been International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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Dovepress
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called   paradoxical bronchoconstriction (or paradoxical 
bronchospasm),6 and describes respiratory events that hap-
pen shortly after administration of a bronchodilator drug, 
suggesting an effect opposite to what would be expected. 
The clearest manifestation of this phenomenon is defined as 
the presence of spontaneously reported respiratory symp-
toms classified according to World Health Organization 
(WHO) preferred terms as ‘bronchospasm’, ‘bronchospasm 
  aggravated’ or ‘bronchospasm paradoxical’. Patients may 
also present with symptoms such as coughing, wheezing and 
dyspnea, possibly accompanied by the need for administra-
tion of rescue medication.7,8 Paradoxical bronchoconstriction 
may sometimes be suggested by a fall in forced expiratory 
volume in one second (FEV1) without any other symptoms.9 
This phenomenon could have several potential causes includ-
ing an adverse reaction either to the drug administered or 
to other constituents of the aerosol such as preservatives, 
surfactants, stabilizers or propellants, solution osmolarity, 
or pH.10 A fall in FEV1 without symptoms may also reflect air-
flow turbulence, and some investigators have suggested that 
repeated spirometry efforts may trigger bronchoconstriction, 
as evidenced by a fall in FEV1 with successive attempts.11–13 
In this context, a fall in FEV1 without symptoms likely does 
not reflect an adverse response to an inhaled substance, but 
rather is the result of the forced exhalation maneuver itself.
The aqueous drug formulation delivered by Respimat® 
SMI contains two excipients, ethylene diamine tetra-acetic 
acid (EDTA) and benzalkonium chloride (BAC), which act 
as stabilizers and preservatives and have been reported to 
induce bronchoconstriction in patients when administered 
by nebulisers.6,14 In pooled analyses of studies in which a 
range of short-acting bronchodilators were given as single 
and repeated doses from Respimat® SMI to asthma and 
COPD patients, no bronchospasm was recorded and levels of 
paradoxical bronchoconstriction were very low.15,16 In asthma 
patients with documented hyperreactivity, four inhalations 
of a placebo equivalent of the tiotropium formulation (the 
usual dose for COPD is only two inhalations) did not produce 
paradoxical bronchoconstriction and was associated with less 
cough than a placebo chlorofluorocarbon (CFC)-pMDI,17 
supporting results of an earlier study that showed no differ-
ence in the degree of fall in FEV1 between placebo aqueous 
or ethanolic inhalations and normal saline (all delivered via 
Respimat® SMI).18
This retrospective analysis used pooled data from nearly 
2000 COPD patients who participated in two randomized, 
placebo-controlled, clinical trials that used identical   protocols, 
and whose main objective was to assess the efficacy and 
safety of 48 weeks’ treatment with tiotropium delivered via 
Respimat® SMI. A pooled analysis of the primary outcomes 
of these two studies has already been reported.19 The aim of 
the study was to quantify paradoxical bronchoconstriction 
and grade adverse events that could indicate the occurrence 
of this phenomenon after administration of tiotropium via 
Respimat® SMI.
Materials and methods
study details
The present study is a retrospective analysis of pooled 
data from two international clinical trials in which 1990 
patients with COPD received 48 weeks’ treatment with 
once-daily tiotropium (5 or 10 µg; Boehringer Ingelheim, 
Ingelheim, Germany) or placebo, inhaled via Respimat® SMI 
  (Boehringer Ingelheim, Ingelheim, Germany).19 Both active 
and placebo formulations contained EDTA and BAC. The 
two trials (NCT00168831 and 00168844) followed the same 
randomized, double-blind, parallel-group design, and their 
protocols were approved by the appropriate ethics review 
bodies. The three treatment arms were well balanced with 
respect to patient characteristics: the mean age of all patients 
was 65.0 years, they had a mean pre-bronchodilator FEV1 
of 1.06 L (37.7% of predicted normal) and a mean ratio of 
pre-bronchodilator FEV1 to forced vital capacity (FVC) of 
0.42 (Table 1).19
Tolerability assessments
We recorded the incidence in the three treatment arms of 
pre-defined respiratory events that occurred during the 
30   minutes immediately following inhalation of study treat-
ment on each of the eight test days during the two trials 
(days 1, 15, 57, 113, 169, 225, 281, and 337). The events of 
interest were defined as follows:
1.  Bronchospasm or aggravated bronchospasm, a spon-
taneously reported adverse event which was recorded 
by the investigator as “aggravated” or “paradoxical” 
bronchospasm.
2.  Any respiratory adverse event other than broncho-
spasm that could indicate administration-related 
  bronchoconstriction. These were recorded under a 
search category in MedDRA (Medical Dictionary for 
Regulatory Activities) that was defined   specifically 
for the two trials and are referred to hereafter as 
 administration-related bronchoconstriction indicators 
(ARBIs). These comprised 28 different MedDRA pre-
ferred terms such as dyspnea, wheezing, cough, and chest 
discomfort (Table 2).International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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3.  Documented use of rescue medication (salbutamol pMDI 
100 µg per inhalation).
4.  A fall of $15% in FEV1 below test-day pre-dose value 
without other symptoms and without the need for rescue 
medication.
FEV1 was measured as part of the planned spirometry 
assessments performed on each test day in the two trials. No 
bronchodilator (other than the study treatment) was admin-
istered during FEV1 measurements, which were performed 
10 minutes before study treatment administration, then 5 and 
30 minutes and 1, 2, and 3 hours afterwards.
As some of the above events are more suggestive of 
administration-related bronchoconstriction than others, four 
mutually exclusive categories (A–D) were defined (A = most 
suggestive, D = least suggestive) as follows.
•	 Category A – Aggravated bronchospasm (with or without 
other events).
•	 Category B – A combination of at least two of these 
three events: rescue medication use, ARBIs, and an 
  asymptomatic fall in FEV1 of $15% from test-day pre-
dose value.
•	 Category C – Either rescue medication use or ARBIs (but 
not both).
•	 Category D – Asymptomatic fall in FEV1 of $15% 
from test-day pre-dose value, not requiring rescue 
medication.
statistical analysis
Data from the two trials were pooled and grouped by treat-
ment arm. Within each of the four categories, the number 
of patients who experienced qualifying events on one or 
more test days was totaled. The number of patients reporting 
events on each test day was also recorded, to examine any 
temporal trend over the treatment period. A post-hoc analysis 
was performed to compare whether the overall severity of 
events differed between treatments, comparing all patients in 
the two tiotropium groups with patients in the placebo group 
by ordinal logistic regression.
Results
The number of patients who reported each category of 
event on one or more test days is shown in Table 3. 
(Note: Patients appear in one category only – the worst 
category of event experienced.) The number who reported 
  Category B, C, and D events (as a proportion of all patients 
tested on each day) are shown in Figure 1. As patients 
withdrew from the study for various reasons during the 
48-week treatment period, the numbers of patients tested 
on each test day gradually declined as the study progressed 
(Table 4).
No  patients  reported  aggravated  bronchospasm 
(Category A). Category B events were very uncommon, being 
  experienced by six patients (0.3%) – two and three patients 
in the tiotropium 5 and 10 µg groups, respectively, and one 
in the placebo group. The events were recorded during the 
Table 1 Baseline characteristics of the 1990 patients with COPD in the present study
Characteristic Tiotropium Respimat® 5 μg 
(n = 670)
Tiotropium Respimat® 
10 μg (n = 667)
Placebo Respimat® 
(n = 653)
number of men  491 (73.3%) 498 (74.7%) 487 (74.6%)
Age (years) 64.7 (8.6) 65.1 (8.5) 65.2 (8.7)
Duration of COPD (years) 8.3 (6.4) 9.0 (7.4) 9.5 (7.5)
Pre-bronchodilator FeV1 (L)  1.066 (0.398) 1.065 (0.403) 1.058 (0.388)
Pre-bronchodilator FeV1 (% predicted normal) 38.0 (11.7) 37.7 (11.7) 37.5 (11.6)
FeV1/FVC ratio 0.42 (0.11) 0.42 (0.11) 0.42 (0.11)
FeV1 reversibility to salbutamol (%)a 19.9 (21.4) 19.4 (18.1) 20.8 (37.4)
Current smokers (%) 37.9 34.8 36.1
Notes: Other than numbers and/or proportions, data shown are means (and standard deviation). aValue from screening visit.
Abbreviations: COPD, chronic obstructive pulmonary disease; FeV1, forced expiratory volume in 1 second; FVC, forced vital capacity.
Table  2  List  of  MedDrA  preferred  terms  (other  than  bron-
chospasm  and  bronchospasm  paradoxical)  that  could  possibly 
indicate ArB
O Asthma
O Bronchial hyperactivity
O Bronchial obstruction
O Bronchial edema
O Chest discomfort
O Chest pain
O Cough
O COPD
O COPD exacerbated
O Dyspnea
O Dyspnea at rest
O Dyspnea exacerbated
O Dyspnea exertional
O Hyperventilation
O Increased bronchial secretion
O   Increased viscosity of bronchial 
secretion
O Intercostal retraction
O Obstructive airways disorder
O   Obstructive chronic bronchitis with 
acute exacerbation
O Productive cough
O Pulmonary congestion
O respiration abnormal
O respiratory tract congestion
O reversible airways obstruction
O status asthmaticus
O suffocation feeling
O Tachypnea
O Wheezing
Abbreviations: ArB, administration-related bronchoconstriction; COPD, chronic 
obstructive pulmonary disease; MedDrA, Medical Dictionary for regulatory Activities.International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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Table 3 number of patients (and % of total) with respiratory events suggestive of administration-related bronchoconstriction during 
the 30 minutes immediately after inhalation of study treatment on at least one test day. Patients are grouped according to the worst 
category of event experienced. See text for detailed definition of categories
Number of test 
days on which 
event occurred
Tiotropium 
Respimat® 5 μg 
(n = 670)
Tiotropium 
Respimat® 10 μg  
(n = 667)
Placebo 
Respimat® 
(n = 653)
number of patient tests (n) 4850 4731 4232
Category A (aggravated bronchospasm) At least 1 0 (0) 0 (0) 0 (0)
Category B (two or more of rescue use,  
ArBI, and 15% fall in FeV1)
At least 1
1
2 (0.3)
2
3 (0.4)
3
1 (0.2)
1
Category C (either rescue use or ArBI) At least 1
1
2
3
8 (1.2)
7
0
1
5 (0.7)
5
0
0
8 (1.2)
8
0
0
Category D (15% fall in FeV1) At least 1
1
2
3
4
45 (6.7)
33
8
4
0
64 (9.6)
52
8
4
0
95 (14.5)
67
20
7
1
none of the above At least 1
1
2
3
4
5
6
7
8
615 (91.8)
14
23
21
11
18
1
17
501
595 (89.2)
13
30
25
17
17
12
23
458
549 (84.1)
37
53
25
22
20
19
11
362
Abbreviations: ArBI, administration-related bronchoconstriction indicator; FeV1, forced expiratory volume in one second.
later stages of the two studies (days 225, 281, and 337). 
Despite being recorded throughout the studies, Category 
C events were also uncommon. They were experienced by 
no more than three patients in any treatment group on any 
test day (#0.6%) and the total incidence in the two active 
treatment groups (13/1337; 1.0%) was very similar to that 
in the placebo group (8/653; 1.2%). There was no indication 
of a relationship between adverse event incidence and tiotro-
pium dose. Category D events (asymptomatic falls in FEV1 
of $15%) were experienced throughout the studies, with no 
evidence of a change in incidence over time. They affected 
45/670 (6.7%) in the 5 µg group and 64/667 (9.6%) in the 
10 µg group (total incidence in tiotropium groups, 8.2%) and 
95/653 (14.5%) in the placebo group.
A post-hoc analysis showed that the odds of experiencing 
a less severe event were significantly higher in patients in 
the two tiotropium groups combined than in patients in 
the placebo group (odds ratio = 3.25, 95% confidence 
interval = 1.86–5.68; P , 0.0001).
Discussion
This retrospective analysis shows that events which are 
suggestive of administration-related bronchoconstriction 
are rare in COPD patients receiving tiotropium delivered 
via Respimat® SMI for 48 weeks in a clinical trial setting. 
No patients reported bronchospasm (Category A), and only 
six (0.3%) and 21 (1.1%) of 1990 patients, respectively, 
reported Category B and C events (which, after bronchos-
pasm, were the next most important categories of events that 
could suggest administration-related bronchoconstriction). 
The most commonly occurring events were asymptomatic 
falls in FEV1 of $15%, the category which is the least sug-
gestive of paradoxical   bronchoconstriction. In the clinical 
trials included in this analysis, pulmonary function tests were 
performed in triplicate to establish reproducibility. Some 
studies have suggested that repeated spirometry efforts may 
act as a trigger for bronchoconstriction, as evidenced by a 
fall in FEV1 with successive attempts.11–13 Consequently, 
the incidence of Category D events reported in this analysis 
may not reflect administration-induced paradoxical bron-
choconstriction alone, but may in part be due to repeated 
spirometric maneuvers.
The amounts of BAC and EDTA present in aqueous 
solutions delivered by Respimat® SMI are much lower (by a 
factor of $500) than the doses reported to induce bronchoc-
onstriction when inhaled from a nebulizer.6,14 The tiotropium International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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solution in Respimat® SMI contains 100 µg/mL each of 
EDTA and BAC, which corresponds to about 1 µg of each 
excipient per actuation (volume per actuation = 11 µL). 
Thus, based on a lung deposition fraction of approximately 
40% of the inhaled dose, as achieved in healthy volunteers 
who inhaled an aqueous formulation similar to that in 
tiotropium Respimat®,20 the approximate lung exposure of 
EDTA and BAC from a single actuation would be 0.40 µg 
each. Indeed, in single- and repeated-dose studies in which 
short-acting bronchodilators were inhaled from Respimat® 
SMI by patients with asthma or COPD, the incidence of 
adverse reactions was very similar to that recorded with 
pMDI formulations, which contain no BAC or EDTA, and 
the reactions were limited mainly to an asymptomatic decline 
in FEV1.15,16
Although the tiotropium solution in Respimat® SMI 
contains five times less EDTA than the corresponding iprat-
ropium/fenoterol formulation, twice as much BAC (0.80 µg) 
is delivered at each dosing point with tiotropium as with ipra-
tropium/fenoterol because the standard dose of tiotropium 
requires two actuations from Respimat® SMI, as opposed to 
only one actuation for the ipratropium/fenoterol formulation. 
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Figure 1 Proportion of patients (%) with respiratory events suggestive of administration-related bronchoconstriction during the 30 minutes immediately after inhalation of 
study treatment on each test day. events are shown by treatment for Categories B–D (no Category A events occurred), and patients are grouped according to the worst 
category of event experienced. The number of patients tested on each day fell as the study progressed (see Table 4). See text for definition of categories.
Table 4 number of patients tested on each test day
Test day Tiotropium 
Respimat®  
5 μg (n = 670) 
Tiotropium  
Respimat®  
10 μg (n = 667) 
Placebo  
Respimat® 
(n = 653)
1 670  667 653
15 649  647 604
57 628 620 549
113 608 590 524
169 593 572 496
225 576 554 476
281 564 539 458
337 562 542 472International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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This, and the fact that the tiotropium solution is more acidic 
than the ipratropium/fenoterol formulation (pH values of 2.9 
and 3.4 respectively), could increase its potential to cause 
bronchial irritation. In spite of this, our analysis shows that 
administration-related bronchoconstriction is uncommon 
when tiotropium is administered via Respimat® SMI for 
48 weeks in COPD patients. Our finding is consistent with 
results of studies in hyperreactive asthma patients who 
were given four inhalations of a placebo equivalent of the 
tiotropium formulation from Respimat® SMI (twice the usual 
tiotropium dose).17,18
In the context of our analysis, the placebo group from 
the clinical trial is not a true placebo group, as despite the 
absence of tiotropium, the formulation still contained the 
same amount of BAC and EDTA as in the two tiotropium 
inhalers. Nevertheless, the placebo data do provide use-
ful insights. For example, the difference in incidence of 
asymptomatic FEV1 falls between tiotropium and placebo 
(8.2% and 14.5%, respectively), suggesting that the pres-
ence of the bronchodilator provides a measure of protection 
against any administration-related bronchoconstriction, in 
agreement with a previous retrospective analysis of clinical 
trials of ipratropium/fenoterol and ipratropium.16 When the 
average incidence of events over all test days in our analysis 
are calculated and compared, the frequency of asymptomatic 
falls in FEV1 (Category D) for tiotropium (1.5%) is very 
similar to values reported from studies in asthma and COPD 
patients that measured the incidence of falls in either FEV1 or 
peak expiratory flow soon after inhalation from pMDIs.21,22 
Moreover, the values of 1.5% for tiotropium and 3.15% for 
placebo in our analysis are slightly lower than those previ-
ously reported for COPD patients (2% for active and 5.6% 
for placebo).16
These observations suggest that the incidence of events 
indicative of paradoxical bronchoconstriction in COPD 
patients who receive long-term treatment with tiotropium 5 
or 10 µg via Respimat® SMI is very low.
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